|
| For further information or copies of the full articles please contact us at (303) 317-3489 or support@cemines.com |
|
|
|
|
|
January 11, 2006 CeMines® granted European Union regulatory clearance and CE Mark registration of its Cell Correct LAb® clinical Dx test for lung cancer
November 30, 2005 CeMines® receives multiple USPTO Patent-Issue Notifications, two of which protect its discovery of a significant new class of oncology targets for diagnostic and therapeutic applications
September 13, 2005 CeMines® and Colorado Heart & Body Imaging form Strategic Alliance to use the CellCorrect™ LAb test in a novel imaging program for the detection of Lung Cancer
July 7, 2005 CeMines® receives Notice of Allowance from U.S. Patent & Trademark Office related to its discovery of a significant new class of oncology targets for diagnostic and therapeutic applications
July 3, 2005 CeMines® presents updated diagnostic data and announces the filing of two therapeutic patents at The World Biomarker Congress 2005
April 27, 2005 Clinical Trial Results Validate CeMines® Molecular FingerPrinting™ Profiles of Lung Cancer Biomarker Patterns, Confirming "High Level of Confidence"
March 31, 2005 CeMines® presented with "Innovative Technology Award" for 2004 by Jefferson Economic Council (JEC)
February 24, 2005 CeMines® selected to present at American Association for Cancer Research (AACR)
January 18, 2005 CeMines® elects Dr. K.C. Nicolaou as Co-Chairman, Scientific Advisory Board
December 3, 2004 CeMines® Inc. creates International Division
November 4, 2004 CeMines® introduces TrialVial™
October 14, 2004 CeMines® Molecular FingerPrinting™ technology featured by MD BuyLine in its Current “Leading Edge Report”
October 12, 2004 MD BUYLINE features CeMines® in article titled, "Molecular FingerPrinting™ will Revolutionize Cancer Testing"
2004 Pharmaceutical Executive Article Better Drugs Through Diagnostics: CeMines hopes to improve cancer drugs by developing a screening test that helps determine the right therapy.
October 30, 2003 CeMines enters into marketing-and-sales partnership with Serologicals’ Chemicon International Division
October 15, 2003 CeMines enters into marketing-and-sales partnership with Sigma Aldrich
January 31, 2003 CeMines presents basics of new molecular diagnostics based on the detection of tumor specifics gene splicing and mechanism-of-action rationale for company’s Molecular FingerPrinting™ platform |
|
|
|
|
